1. Home
  2. VYGR vs GOSS Comparison

VYGR vs GOSS Comparison

Compare VYGR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • GOSS
  • Stock Information
  • Founded
  • VYGR 2013
  • GOSS 2015
  • Country
  • VYGR United States
  • GOSS United States
  • Employees
  • VYGR N/A
  • GOSS N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • GOSS Biotechnology: Pharmaceutical Preparations
  • Sector
  • VYGR Health Care
  • GOSS Health Care
  • Exchange
  • VYGR Nasdaq
  • GOSS Nasdaq
  • Market Cap
  • VYGR 222.9M
  • GOSS 188.6M
  • IPO Year
  • VYGR 2015
  • GOSS 2019
  • Fundamental
  • Price
  • VYGR $3.16
  • GOSS $0.84
  • Analyst Decision
  • VYGR Strong Buy
  • GOSS Strong Buy
  • Analyst Count
  • VYGR 9
  • GOSS 4
  • Target Price
  • VYGR $14.86
  • GOSS $7.50
  • AVG Volume (30 Days)
  • VYGR 396.9K
  • GOSS 1.5M
  • Earning Date
  • VYGR 05-12-2025
  • GOSS 05-06-2025
  • Dividend Yield
  • VYGR N/A
  • GOSS N/A
  • EPS Growth
  • VYGR N/A
  • GOSS N/A
  • EPS
  • VYGR N/A
  • GOSS N/A
  • Revenue
  • VYGR $80,001,000.00
  • GOSS $114,701,000.00
  • Revenue This Year
  • VYGR N/A
  • GOSS N/A
  • Revenue Next Year
  • VYGR $2.04
  • GOSS $172.31
  • P/E Ratio
  • VYGR N/A
  • GOSS N/A
  • Revenue Growth
  • VYGR N/A
  • GOSS N/A
  • 52 Week Low
  • VYGR $2.75
  • GOSS $0.50
  • 52 Week High
  • VYGR $9.55
  • GOSS $1.55
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 38.34
  • GOSS 37.58
  • Support Level
  • VYGR $2.75
  • GOSS $0.80
  • Resistance Level
  • VYGR $3.34
  • GOSS $0.88
  • Average True Range (ATR)
  • VYGR 0.26
  • GOSS 0.10
  • MACD
  • VYGR 0.03
  • GOSS -0.01
  • Stochastic Oscillator
  • VYGR 41.41
  • GOSS 20.24

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: